Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Pneumonia Therapeutics Market
Pneumonia Therapeutics Market Share
- Report ID: GMI2029
- Published Date: Jun 2020
- Report Format: PDF
Pneumonia Therapeutics Market Share
Some of the prominent market players operating in the pneumonia therapeutics market share include:
- Allergan
- Bayer
- Merck
- Pfizer
- Sanofi
- Abbott
- Cipla
- GlaxoSmithKline
- Lupin Pharmaceuticals
- Novartis
- Mylan
These market players are undertaking various organic and inorganic growth strategies to capture higher market share in pneumonia therapeutics.
- In September 2018, Pfizer received breakthrough therapy designation from the U.S. FDA for its 20-Valent Pneumococcal Conjugate Vaccine. This vaccine is useful for the prevention of pneumonia and invasive disease. This strategy enhanced the company’s product portfolio.
- In June 2019, Merck received FDA approval for Zerbaxa drug. This drug is used in the treatment of ventilator associated pneumonia and hospital acquired bacterial pneumonia. This strategy widened the firm’s pneumonia therapeutics portfolio.
Frequently Asked Questions (FAQ) :
The market size of pneumonia therapeutics exceeded USD 1.7 billion in 2019.
The industry share of pneumonia therapeutics will grow at 7.6% CAGR from 2020 to 2026.
Antiviral drugs segment will witness around 7.5% CAGR during the forecast period.
Asia Pacific accounted for more than 34% market share, says this GMI report.
Hospital-acquired pneumonia market accounted for more than USD 352 Mn in 2019.
Key industry players include Allergan, Bayer, Merck, Pfizer, Sanofi, Abbott, Cipla, GlaxoSmithKline, Lupin Pharmaceuticals, Novartis, and Mylan.
Pneumonia Therapeutics Market Scope
×
Get a free sample of
Pneumonia Therapeutics Market
Inquiry Before Buying
Get special pricing options on this report
Request Sectional Data
Over 70% of our clients customize reports to fit their needs. Please tell us how you would like to customize yours
below